Prakash Seshadri, MD
Endocrinology, Diabetes & Metabolism · Wilmington, DENPI 1134144330
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $875 of the $1,261 with a category attached, or 69.4%. 14 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 27.8% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in DE, where the typical reported total is $1,261.
Across 38 payments — averaging $33.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$350
- Abbott$166
- Lilly USA, LLC$158
- Medtronic$94
- Boehringer Ingelheim$86
- Novo Nordisk$82
- plus $325 from 8 others
What the payments were for
- Speaking & faculty fees$35028%
- Food & beverage$87569%
- Education$363%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 1 | $350 |
| Abbott | 9 | $166 |
| Lilly USA, LLC | 3 | $158 |
| Medtronic | 4 | $94 |
| Boehringer Ingelheim | 4 | $86 |
| Novo Nordisk | 3 | $82 |
| Sequel Med Tech, LLC | 3 | $80 |
| Amgen(2 entities) | 3 | $66 |
| Tandem Diabetes Care, Inc. | 2 | $53 |
| Shire North American Group Inc | 2 | $45 |
| Dexcom, Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $20 |
| Mannkind Corporation | 1 | $20 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$350
- MOUNJARO$122
How this compares
$1,261 in reported general payments places this provider in the 50th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
See all endocrinology, diabetes & metabolism providers in Delaware →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 326 | $635,794 |
| TrulicityDulaglutide | 210 | $428,452 |
| MounjaroTirzepatide | 152 | $250,940 |
| JardianceEmpagliflozin | 148 | $214,603 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 59 | $101,451 |
| RybelsusSemaglutide | 52 | $101,047 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $84,114 |
| JanuviaSitagliptin Phosphate | 72 | $78,808 |
| Tresiba Flextouch U-100Insulin Degludec | 92 | $58,312 |
| FarxigaDapagliflozin Propanediol | 44 | $53,237 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 107 | $52,963 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 52 | $49,602 |
| Humalog Kwikpen U-100Insulin Lispro | 105 | $32,636 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 201 | $29,911 |
| Novolog FlexpenInsulin Aspart | 93 | $29,493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $82 | $741,404392 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $158 | $679,392362 claims |
| Boehringer IngelheimJardiance, Tradjenta | $86 | $227,448161 claims |
| MerckJanuvia, Janumet | $18 | $102,48987 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
Other endocrinology, diabetes & metabolism in Wilmington
- Franklin ThelmoWilmington$872
- Amanda McKennaWilmington$680
- William JaffeeWilmington$322
- Amy WachterWilmington$256
- Ripudaman HundalNewark$370K
- Nira MadisiMilford$23K
- Francisco PadillaSeaford$22K
- Reetu SinghLewes$9K
- Joanna KhatibMillsboro$7K
- Chitra ChoudharyDover$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.